$598 Million is the total value of Atlas Venture Life Science Advisors, LLC's 16 reported holdings in Q2 2022. The portfolio turnover from Q1 2022 to Q2 2022 was 5.9% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| DAWN | Buy | Day One Biopharmaceuticals, Inc. | $160,533,000 | +97.3% | 8,968,305 | +9.3% | 26.84% | +160.9% |
| KYMR | Kymera Therapeutics, Inc. | $135,382,000 | -53.5% | 6,875,698 | 0.0% | 22.63% | -38.5% | |
| DYN | Dyne Therapeutics, Inc. | $61,383,000 | -28.7% | 8,934,902 | 0.0% | 10.26% | -5.8% | |
| REPL | Replimune Group, Inc. | $56,104,000 | +2.9% | 3,209,627 | 0.0% | 9.38% | +36.1% | |
| GBIO | Generation Bio, Co. | $54,309,000 | -10.6% | 8,278,876 | 0.0% | 9.08% | +18.2% | |
| AVTE | Sell | Aerovate Therapeutics, Inc. | $41,237,000 | -27.5% | 2,638,297 | -15.0% | 6.89% | -4.2% |
| IKNA | Ikena Oncology, Inc. | $22,231,000 | -27.4% | 5,018,178 | 0.0% | 3.72% | -4.0% | |
| AKRO | Akero Therapeutics, Inc. | $21,095,000 | -33.4% | 2,232,251 | 0.0% | 3.53% | -11.9% | |
| Vigil Neuroscience, Inc. | $15,059,000 | -63.3% | 5,836,874 | 0.0% | 2.52% | -51.5% | ||
| GMTX | Gemini Therapeutics, Inc. | $8,880,000 | +21.6% | 5,254,365 | 0.0% | 1.48% | +60.9% | |
| Xilio Therapeutics, Inc. | $8,057,000 | -58.7% | 2,759,344 | 0.0% | 1.35% | -45.4% | ||
| MGTA | Magenta Therapeutics, Inc. | $4,172,000 | -58.6% | 3,476,536 | 0.0% | 0.70% | -45.3% | |
| AVRO | AvroBio, Inc. | $4,159,000 | -30.3% | 4,520,863 | 0.0% | 0.70% | -7.9% | |
| FSTX | F-star Therapeutics, Inc. | $3,753,000 | +76.4% | 599,524 | 0.0% | 0.63% | +133.1% | |
| VRDN | Viridian Therapeutics, Inc. | $1,042,000 | -37.4% | 90,072 | 0.0% | 0.17% | -17.1% | |
| SPRO | Spero Therapeutics, Inc. | $764,000 | -91.5% | 1,031,160 | 0.0% | 0.13% | -88.7% | |
| COGT | Exit | Cogent Biosciences, Inc. | $0 | – | -186,487 | -100.0% | -0.18% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-08-03
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Kymera Therapeutics, Inc. | 8 | Q3 2023 | 40.1% |
| Day One Biopharmaceuticals, Inc. | 8 | Q3 2023 | 26.8% |
| Dyne Therapeutics, Inc. | 8 | Q3 2023 | 15.4% |
| Replimune Group, Inc. | 8 | Q3 2023 | 9.4% |
| Generation Bio, Co. | 8 | Q3 2023 | 9.1% |
| Aerovate Therapeutics, Inc. | 8 | Q3 2023 | 7.2% |
| Akero Therapeutics, Inc. | 8 | Q3 2023 | 4.3% |
| Ikena Oncology, Inc. | 8 | Q3 2023 | 5.8% |
| Xilio Therapeutics, Inc. | 8 | Q3 2023 | 4.1% |
| AVROBIO INC | 8 | Q3 2023 | 1.6% |
View Atlas Venture Life Science Advisors, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-09 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-09 |
| 13F-HR | 2022-08-03 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-05-16 |
View Atlas Venture Life Science Advisors, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.